Logo image of ARDX

ARDELYX INC (ARDX) Stock Price, Quote, News and Overview

NASDAQ:ARDX - Nasdaq - US0396971071 - Common Stock - Currency: USD

3.68  +0.04 (+1.1%)

After market: 3.68 0 (0%)

ARDX Quote, Performance and Key Statistics

ARDELYX INC

NASDAQ:ARDX (6/6/2025, 5:59:48 PM)

After market: 3.68 0 (0%)

3.68

+0.04 (+1.1%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High8.06
52 Week Low3.21
Market Cap880.48M
Shares239.26M
Float233.62M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE30.71
Earnings (Next)07-30 2025-07-30/bmo
IPO06-19 2014-06-19


ARDX short term performance overview.The bars show the price performance of ARDX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

ARDX long term performance overview.The bars show the price performance of ARDX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 100 200 300 400 500

The current stock price of ARDX is 3.68 USD. In the past month the price increased by 1.1%. In the past year, price decreased by -42.95%.

ARDELYX INC / ARDX Daily stock chart

ARDX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.48 335.32B
AMGN AMGEN INC 13.99 156.11B
GILD GILEAD SCIENCES INC 14.53 139.89B
VRTX VERTEX PHARMACEUTICALS INC N/A 115.69B
REGN REGENERON PHARMACEUTICALS 11.13 53.25B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 39.23B
ARGX ARGENX SE - ADR 101.9 35.78B
ONC BEONE MEDICINES LTD-ADR 6.54 27.66B
BNTX BIONTECH SE-ADR N/A 26.08B
NTRA NATERA INC N/A 22.36B
BIIB BIOGEN INC 8.42 19.51B
SMMT SUMMIT THERAPEUTICS INC N/A 15.29B

About ARDX

Company Profile

ARDX logo image Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The company is headquartered in Waltham, Massachusetts and currently employs 395 full-time employees. The company went IPO on 2014-06-19. The firm has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. The company has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.

Company Info

ARDELYX INC

400 Fifth Ave, Suite 210

Waltham MASSACHUSETTS 94555 US

CEO: Michael Raab

Employees: 395

ARDX Company Website

ARDX Investor Relations

Phone: 15107457047

ARDELYX INC / ARDX FAQ

What is the stock price of ARDELYX INC today?

The current stock price of ARDX is 3.68 USD. The price increased by 1.1% in the last trading session.


What is the ticker symbol for ARDELYX INC stock?

The exchange symbol of ARDELYX INC is ARDX and it is listed on the Nasdaq exchange.


On which exchange is ARDX stock listed?

ARDX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ARDELYX INC stock?

18 analysts have analysed ARDX and the average price target is 10.52 USD. This implies a price increase of 185.99% is expected in the next year compared to the current price of 3.68. Check the ARDELYX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ARDELYX INC worth?

ARDELYX INC (ARDX) has a market capitalization of 880.48M USD. This makes ARDX a Small Cap stock.


How many employees does ARDELYX INC have?

ARDELYX INC (ARDX) currently has 395 employees.


What are the support and resistance levels for ARDELYX INC (ARDX) stock?

ARDELYX INC (ARDX) has a support level at 3.63 and a resistance level at 3.86. Check the full technical report for a detailed analysis of ARDX support and resistance levels.


Is ARDELYX INC (ARDX) expected to grow?

The Revenue of ARDELYX INC (ARDX) is expected to grow by 12.15% in the next year. Check the estimates tab for more information on the ARDX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ARDELYX INC (ARDX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ARDELYX INC (ARDX) stock pay dividends?

ARDX does not pay a dividend.


When does ARDELYX INC (ARDX) report earnings?

ARDELYX INC (ARDX) will report earnings on 2025-07-30, before the market open.


What is the Price/Earnings (PE) ratio of ARDELYX INC (ARDX)?

ARDELYX INC (ARDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.22).


What is the Short Interest ratio of ARDELYX INC (ARDX) stock?

The outstanding short interest for ARDELYX INC (ARDX) is 11.89% of its float. Check the ownership tab for more information on the ARDX short interest.


ARDX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ARDX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ARDX. ARDX has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ARDX Financial Highlights

Over the last trailing twelve months ARDX reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS increased by 20.36% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -13.11%
ROE -36.91%
Debt/Equity 1.04
Chartmill High Growth Momentum
EPS Q2Q%-54.55%
Sales Q2Q%61.04%
EPS 1Y (TTM)20.36%
Revenue 1Y (TTM)127.34%

ARDX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to ARDX. The Buy consensus is the average rating of analysts ratings from 18 analysts.

For the next year, analysts expect an EPS growth of -138.35% and a revenue growth 12.15% for ARDX


Ownership
Inst Owners64.68%
Ins Owners1.84%
Short Float %11.89%
Short Ratio4.75
Analysts
Analysts86.67
Price Target10.52 (185.87%)
EPS Next Y-138.35%
Revenue Next Year12.15%